Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), spoke on common stigmas regarding HS and how clinicians can improve consultation through a culturally sensitive approach.
There are several misconceptions regarding hidradenitis suppurativa (HS) that clinicians should address with a culturally sensitive approach, said Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with HS.
Transcript
Can you speak on misconceptions in the management of HS?
We understand fully that cigarette smoking and weight loss are very important topics. Cigarette smoking can kill you—it's been proven, it's very bad for you—and being overweight is indicative of being unhealthy and we get that, too. If I meet a doctor, and in the first 30 minutes, they tell me that I need to quit smoking and lose weight, I kind of tune them out.
We are working, as the patient community, to kind of help doctors understand that we have organized online and we know a lot of patients who are thin that have this disease. There are patients who have anorexia that have this disease. And again, I'm not saying that we shouldn't be trying to incorporate a healthy diet into our lifestyle, that smoking isn't horrible for you—it absolutely is—but maybe that can be a nudge in the second or third appointment and done gently.
This reputation that patients with HS have that we’re overweight smokers only leads into more of this stigma that we are doing this to ourselves. If it were as simple as that we would do this, but it's a little more complex than that.
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL
September 16th 2025Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.
Read More